CD274 and neoplasm: As the first anti-PD-L1 monodomain antibody drug for tumor immunotherapy in clinical research and the first immunotherapy antibody drug adopting subcutaneous injection 20, KN035 has shown good safety and effectiveness in preclinical research and phase II/III clinical trials for various tumors 21, 22.